rpl-5 Antibody

What is RPL5 and why is it significant in research?

RPL5 is a component of the 60S subunit of ribosomes and forms part of the 5S ribonucleoprotein particle (5S RNP), which is essential for rRNA formation and maturation . Beyond its canonical role in translation, RPL5 also exhibits extra-ribosomal functions including regulation of gene expression, cell cycle control, and modulation of cell proliferation and apoptosis . Its significance in research stems from its involvement in various diseases: mutations in the RPL5 gene are associated with Diamond-Blackfan anemia (a form of red blood cell aplasia) and some cases of pediatric T-cell acute lymphoblastic leukemia . Additionally, RPL5 has been implicated in cancer progression, making it an important target for oncology research .

What applications are RPL5 antibodies suitable for?

RPL5 antibodies are primarily validated for Western Blotting (WB) applications based on the available search results . The antibodies have demonstrated effectiveness in detecting endogenous RPL5 protein with a molecular weight of approximately 34 kDa . While Western Blotting is the confirmed application, researchers should validate the antibody for other potential applications such as immunohistochemistry, immunofluorescence, or immunoprecipitation before use in those contexts.

What is the recommended protocol for using RPL5 antibody in Western Blotting?

For optimal results in Western Blotting, the recommended dilution for RPL5 antibody is 1:1000 . The protocol should involve standard Western Blotting procedures including:

• Protein extraction from cells or tissues of interest

• Protein quantification and normalization

• SDS-PAGE separation of proteins

• Transfer to a membrane (PVDF or nitrocellulose)

• Blocking with appropriate blocking buffer

• Primary antibody incubation with RPL5 antibody at 1:1000 dilution

• Washing steps

• Secondary antibody incubation

• Washing steps

• Detection using chemiluminescence or other appropriate methods

When working with RPL5 antibody, it's important not to aliquot the antibody to maintain its stability and performance .

What species reactivity can be expected with RPL5 antibodies?

The RPL5 antibody described in the search results demonstrates reactivity with human (H), mouse (M), rat (R), and monkey (Mk) samples . This cross-reactivity is based on the high sequence homology of the antigen sequence used to produce the antibody. For other species, even if they share 100% sequence homology, reactivity may need to be experimentally validated as it might not be covered under product performance guarantees .

How can RPL5 antibodies be applied in Diamond-Blackfan anemia (DBA) research?

RPL5 antibodies play a crucial role in DBA research, particularly in studying disease mechanisms and potential therapies. In mouse models of DBA, anti-RPL5 antibodies (e.g., Novus Biologic, NBP1-31413) have been used to confirm the downregulation of RPL5 in conditional knockdown systems .

Methodology for DBA research using RPL5 antibodies:

• Generate or obtain appropriate mouse models (e.g., shRNA-mediated Rpl5 knockdown mice)

• Induce RPL5 downregulation (e.g., using doxycycline treatment in conditional models)

• Isolate specific cell populations of interest (e.g., CD71^high Ter119^high erythroid cells)

• Prepare total cell lysates and perform Western blotting using anti-RPL5 antibodies

• Analyze the expression levels of RPL5 and correlate with phenotypic observations

• Compare with control mice to assess the impact of RPL5 deficiency

This approach has successfully demonstrated that RPL5 downregulation leads to reduced GATA1 protein levels (despite normal mRNA levels), which contributes to the erythroid differentiation defects observed in DBA .

What are the considerations for using RPL5 antibodies in cancer research, particularly for colon cancer studies?

When using RPL5 antibodies in cancer research, several important considerations should be addressed:

• Expression level analysis: RPL5 is significantly overexpressed in colon cancer tissues and cell lines compared to adjacent normal tissues and normal colon epithelial cell lines . Western blotting with RPL5 antibodies can effectively detect these differences.

• Correlation with clinical parameters: RPL5 expression levels correlate with clinical stage in colon cancer patients, suggesting its potential as a prognostic marker .

• Functional studies: After RPL5 knockdown, antibodies can verify the efficiency of knockdown and help monitor downstream effects on:

  • Proliferation (measured by CCK-8 assay and colony formation)

  • Migration (assessed by cell scratch assay)

  • Cell cycle progression (particularly G0/G1 phase arrest)

• Signaling pathway analysis: RPL5 antibodies can be used alongside antibodies against MAPK/ERK pathway components (p-MEK1/2, p-ERK, c-Myc, FOXO3) to elucidate the mechanisms by which RPL5 promotes cancer progression .

• Rescue experiments: When using pathway activators (e.g., TBHQ for ERK activation) to reverse the effects of RPL5 knockdown, antibodies are essential for confirming the restoration of pathway activity .

How should researchers address potential non-specific binding when using RPL5 antibodies?

Addressing non-specific binding is crucial for obtaining reliable results with RPL5 antibodies:

What methodological approaches can distinguish between ribosomal and extra-ribosomal functions of RPL5 when using antibodies?

Distinguishing between the canonical ribosomal and non-canonical extra-ribosomal functions of RPL5 requires sophisticated experimental designs:

• Subcellular fractionation: Separate cellular compartments (cytoplasmic, nuclear, nucleolar) and use RPL5 antibodies to track the protein's localization. Extra-ribosomal functions often involve nuclear or nucleoplasmic localization .

• Co-immunoprecipitation (Co-IP): Use RPL5 antibodies for Co-IP to identify interaction partners. Different binding partners may indicate different functional roles (e.g., interaction with MDM2 and p53 suggests a role in stress response, while interactions with components of the MAPK/ERK pathway suggest involvement in proliferation signaling) .

• Proximity ligation assays: Combine RPL5 antibodies with antibodies against suspected interaction partners to visualize and quantify specific protein-protein interactions in situ.

• Polysome profiling: Combine with Western blotting using RPL5 antibodies to distinguish between RPL5 associated with actively translating ribosomes versus free RPL5 that may be involved in extra-ribosomal functions.

• Mutational analysis: Compare the effects of wild-type RPL5 versus mutants that specifically disrupt either ribosomal or extra-ribosomal functions, using antibodies to confirm expression levels.

How should researchers interpret variations in RPL5 detection between different experimental systems?

When encountering variations in RPL5 detection across different experimental systems, consider these analytical approaches:

• Antibody validation: Verify that the antibody recognizes the correct epitope and produces consistent results in your specific experimental system. Different antibodies (e.g., Cell Signaling #14568 vs. Novus Biologic NBP1-31413 vs. Proteintech 29092-1-AP ) may have different specificities and optimal conditions.

• Expression level assessment: Analyze both protein (Western blot) and mRNA (RT-qPCR) levels to determine whether variations are due to transcriptional or post-transcriptional regulation. In some cases, as seen with GATA1 in erythroid cells, mRNA levels may remain unchanged while protein levels are affected by RPL5 deficiency .

• Cell type considerations: Different cell types may exhibit different baseline expression levels of RPL5. For example, colon cancer cell lines show higher RPL5 expression than normal colon epithelial cells .

• Experimental conditions: Factors such as cell confluency, serum starvation, and stress conditions may affect RPL5 expression or localization.

• Data normalization: Ensure appropriate loading controls and normalization methods are used when comparing RPL5 levels between different samples or experimental conditions.

What are the best practices for designing RPL5 knockdown experiments to validate antibody specificity?

Designing effective RPL5 knockdown experiments for antibody validation requires careful consideration:

• siRNA design: Design multiple siRNA sequences targeting different regions of RPL5 mRNA to minimize off-target effects. In published studies, researchers have successfully designed siRPL5 to achieve significant knockdown in colon cancer cell lines .

• Transfection optimization: Optimize transfection conditions for each cell line to achieve maximum knockdown efficiency while minimizing toxicity.

• Time course analysis: Perform a time course to determine the optimal time point for RPL5 protein reduction after siRNA transfection.

• Validation at multiple levels: Confirm knockdown efficiency by both RT-qPCR (mRNA level) and Western blotting (protein level) .

• Functional validation: Include functional assays (e.g., proliferation, migration) to confirm that the observed phenotypes match expected outcomes based on the literature .

• Alternative knockdown approaches: Consider using shRNA-based approaches for more stable knockdown, especially for long-term experiments. This approach has been successfully used in creating conditional Rpl5 mouse models .

How can RPL5 antibodies be utilized to investigate the relationship between ribosomal dysfunction and cancer progression?

RPL5 antibodies are valuable tools for exploring the connections between ribosomal dysfunction and cancer:

• Expression correlation studies: Use RPL5 antibodies to analyze expression levels across different stages of cancer progression. In colon cancer, RPL5 expression correlates with clinical stage, suggesting its potential value as a prognostic marker .

• Pathway analysis: Combine RPL5 antibodies with antibodies targeting cancer-related signaling pathways. Research has shown that RPL5 promotes colon cancer cell proliferation and migration at least partly through activating the MAPK/ERK signaling pathway .

• Ribosomal stress response: Investigate how ribosomal stress affects p53 pathway activation by monitoring RPL5's interaction with MDM2 and p53. Studies with breast cancer cells have shown that treatments like berberine can cause RPL5 to disappear from the nucleolus, coinciding with p53 accumulation in the nucleus .

• Therapeutic target identification: Use RPL5 antibodies to screen for compounds that modulate RPL5 levels or function, potentially identifying new therapeutic approaches for cancers where RPL5 dysregulation is a feature.

• Multi-omics integration: Combine proteomics data (using RPL5 antibodies) with transcriptomics and clinical data to develop comprehensive models of how ribosomal dysfunction contributes to cancer progression.

What methodological approaches are recommended for studying RPL5's role in cell cycle regulation and apoptosis?

To investigate RPL5's involvement in cell cycle regulation and apoptosis, researchers should consider these methodological approaches:

• Cell cycle analysis: After manipulating RPL5 levels (knockdown or overexpression), use flow cytometry to analyze cell cycle distribution. Studies have shown that RPL5 knockdown arrests colon cancer cells in G0/G1 phase .

• Protein expression analysis: Use Western blotting with RPL5 antibodies alongside antibodies against cell cycle regulators (cyclins, CDKs) and apoptosis markers (cleaved caspases, PARP) to establish mechanistic connections.

• Transcriptional analysis: Combine protein-level data with mRNA expression analysis (RT-qPCR) to determine whether RPL5's effects are transcriptional or post-transcriptional.

• Co-immunoprecipitation: Use RPL5 antibodies to identify interaction partners involved in cell cycle regulation and apoptosis pathways.

• Live-cell imaging: Track cell cycle progression and apoptotic events in real-time after manipulating RPL5 levels.

• Rescue experiments: After RPL5 knockdown, attempt to rescue the phenotype by activating downstream pathways (e.g., using MAPK/ERK pathway activators like TBHQ) to confirm the mechanism of action .

How might RPL5 antibodies contribute to understanding the molecular mechanisms of Diamond-Blackfan anemia and potential therapeutic approaches?

RPL5 antibodies are instrumental in elucidating the molecular mechanisms of Diamond-Blackfan anemia (DBA) and developing therapeutic strategies:

• Mouse model characterization: RPL5 antibodies have been used to validate and characterize conditional Rpl5 knockdown mouse models that recapitulate key features of DBA, including anemia, reticulocytopenia, and bone marrow erythroblastopenia .

• Erythroid differentiation analysis: Using RPL5 antibodies in conjunction with markers of erythroid differentiation helps establish how RPL5 deficiency disrupts normal erythropoiesis.

• Translational regulation: Research has shown that RPL5 deficiency affects translation of specific proteins like GATA1 (a key erythroid transcription factor) without affecting mRNA levels . This suggests RPL5 may have selective effects on translation of certain mRNAs.

• Therapeutic screening: RPL5 antibodies can be used to monitor the effectiveness of potential therapeutic interventions aimed at increasing functional RPL5 levels or bypassing the requirement for RPL5 in erythropoiesis.

• Patient stratification: Correlating RPL5 protein levels with disease severity could help stratify DBA patients and personalize treatment approaches.

The development of RPL5-inducible mouse models provides a valuable platform for testing novel DBA therapies, with RPL5 antibodies serving as critical tools for monitoring treatment efficacy at the molecular level .